Baricitinib is a substance that reduces the immune system response, decreasing the action of enzymes that promote inflammation and joint damage in rheumatoid arthritis, so this remedy is able to reduce inflammation, relieving symptoms of the disease such as joint pain and swelling.
However, this drug is not yet approved in Brazil by Anvisa, nor in the United States by the FDA, and can only be purchased in Europe with a prescription, in the form of 2 and 4 mg tablets.
- Baricitinib is indicated for the treatment of moderate to severe rheumatoid arthritis.
- In cases where symptoms do not improve with the use of other anti-rhyming drugs.
Baricitinib treatment should always be guided by a physician, however the recommended starting dose is 4 mg once daily.
However, this dose can be reduced to 2 mg per day, when inflammation is controlled.
Use of this medicine can cause certain side effects such as nausea, acne, weight gain and more frequent onset of respiratory infections.In addition, some patients may also experience changes in blood tests, particularly in the number of platelets and neutrophils.
Baricitinib is contraindicated in pregnant women and people with hypersensitivity to one of the ingredients of the formula.
In addition, this medicine should be used with caution, and to a lesser extent, in older children and patients with hepatic or renal disease.